Revolution Medicines, Inc. (RVMD)

Revolution Medicines' stock price has experienced significant movement, with a notable increase of approximately 49.11% over the past six months and a surge of 212.05% over the last six months. Acquisition rumors involving AbbVie and Merck have caused stock volatility and price increases. The FDA granted Breakthrough Therapy Designation to zoldonrasib (RMC-9805) for patients with KRAS G12D-mutated non-small cell lung cancer. The company is advancing its clinical programs, including the initiation of the global randomized Phase 3 study for RMC-6236 in pancreatic cancer, and expects data readouts in 2026. Revolution Medicines reported a Q3 2025 net loss of $305.2 million and projects full-year 2025 net losses between $1.03 billion and $1.09 billion, while maintaining a strong financial position with $1.93 billion in cash and investments. Insider Mark A. Goldsmith sold 15,394 shares of Revolution Medicines stock in December 2025.

The demand for Revolution Medicines' therapies is primarily driven by clinical trial outcomes, regulatory approvals, and the prevalence of the specific genetically defined cancers it targets, rather than traditional seasonal fluctuations. While there is a general period of seasonal strength for the broader Healthcare sector from April 25 to December 4, the available data for Revolution Medicines is insufficient to create a reliable seasonal profile specifically for RVMD's stock performance. The company's revenue generation is currently primarily through partnerships and collaborations, as it is still in the clinical trial phases for its therapies.

Revolution Medicines, Inc. (RVMD) is a clinical-stage oncology company focused on discovering and developing targeted therapies for genetically defined cancers, particularly those driven by RAS mutations. Founded in 2014, the company operates within the Biotechnology industry and Healthcare sector, focusing on precision oncology. The company aims to transform cancer treatment by creating selective and potent medicines, leveraging a proprietary research and development platform. Its pipeline includes RAS(ON) inhibitors like daraxonrasib (RMC-6236), elironrasib (RMC-6291), and zoldonrasib (RMC-9805), as well as RAS companion inhibitors like RMC-4630, RMC-5552, and RMC-5845.

Revolution Medicines, Inc. is headquartered in Redwood City, California, United States. The company's stock is listed on the Nasdaq Global Select exchange in the US. It is also listed on several European exchanges, including the Stuttgart Stock Exchange, Dusseldorf Stock Exchange, Frankfurt Stock Exchange, Munich Stock Exchange, Hamburg Stock Exchange in Germany, the Berne Stock Exchange in Switzerland, and the Milan Stock Exchange in Italy.

Revolution Medicines is perceived as an innovative player in the precision oncology market, particularly for its focus on RAS-addicted cancers. Analysts have shown strong confidence in the company, with an average rating of "Buy" from eighteen research firms. The company's successful shift of industry focus to larger G12D and pan-RAS opportunities, and its ability to target the "active" state of the RAS protein, have contributed to a positive reputation for scientific innovation. Stock price volatility due to acquisition rumors has impacted market perception of its valuation, but has not negatively affected its scientific or corporate brand reputation.

Revolution Medicines, Inc. has a significant institutional ownership presence, with 684 institutional owners and shareholders holding a total of 211,296,545 shares, representing approximately 87.38% of the company's stock. Major institutional owners include Vanguard Group Inc., Farallon Capital Management Llc., and Janus Henderson Group Plc. Individual ownership includes insiders (approximately 2.22% of the stock) and public companies and individual investors (approximately 12.16% of the stock), with Andrew J.M. Spokes owning the most shares among individual investors.